文献速递心脑血管急症重症综合管理与镇静镇痛

院外心脏骤停后轻度高碳酸血症的成本效益:TAME研究的经济学评价

The cost-effectiveness of mild hypercapnia after out-of-hospital cardiac arrest: a health economic evaluation alongside the TAME study.
PubMed 文献 · Resuscitation · 2025-10-30
一句话结论基于TAME试验的经济学评价显示,院外心脏骤停后目标性轻度高碳酸血症与目标性正常碳酸血症相比,6个月成本和QALY均无显著差异,成本效益高度不确定,需进一步研究。

该研究为TAME随机临床试验预先设定的前瞻性成本效益分析,从医疗保健视角、6个月时间跨度,纳入17个国家63个ICU的1586例院外心脏骤停患者。主要成本效益指标为每质量调整生命年(QALY)的成本,成本按各国资源单位成本乘以资源使用量估算,QALY采用6个月随访时EQ-5D-5L效用值计算。结果显示两组6个月成本和QALY均无显著差异,在每QALY 50,000美元支付意愿阈值下增量净货币效益亦不显著,95%CI同时包含负值和正值。作者认为轻度高碳酸血症的成本效益高度不确定,需进一步研究确定其可能具有经济价值的特定情形。

要点

  • 在17个国家63个ICU的1586例院外心脏骤停患者中,轻度高碳酸血症组与正常碳酸血症组6个月成本和QALY均无显著差异。
  • 在每QALY 50,000美元支付意愿阈值下,增量净货币效益不显著,95%CI同时包含负值和正值。
  • 作者认为,与正常碳酸血症相比,轻度高碳酸血症的成本效益高度不确定。
  • 作者指出需进一步研究确定轻度高碳酸血症可能具有经济价值的特定情形。

适用人群与场景

  • 院外心脏骤停后复苏的成年患者,来自TAME随机临床试验,共1586例,分布于17个国家63个ICU。

研究设计与关键结果

  • 研究类型:TAME随机临床试验预先设定的前瞻性成本效益分析,医疗保健视角,6个月时间跨度。
  • 样本量与中心:1586例患者,63个ICU,17个国家。
  • 干预与对照:目标性轻度高碳酸血症 vs 目标性正常碳酸血症。
  • 主要终点:每QALY成本;6个月时两组成本和QALY均无显著差异。
  • 增量净货币效益:在每QALY 50,000美元支付意愿阈值下不显著,95%CI同时包含负值和正值。

证据类型、等级与局限

  • 证据类型:随机临床试验(TAME)预先设定的前瞻性成本效益分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,轻度高碳酸血症的成本效益高度不确定,需进一步研究确定其可能具有经济价值的特定情形。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Out of hospital cardiac arrest (OHCA) is a significant public health problem associated with high mortality and high healthcare costs. The Targeted Therapeutic Mild Hypercapnia after Resuscitated Cardiac Arrest (TAME) randomised clinical trial showed that targeted mild hypercapnia did not lead to better neurologic outcomes at 6 months compared to normocapnia after OHCA. We aimed to estimate the cost-effectiveness of mild hypercapnia compared to targeted normocapnia using data from the TAME trial.

METHODS: Pre-specified, prospective cost-effectiveness analysis alongside the TAME RCT from a healthcare perspective using a 6-month time horizon. The analysis included 1586 patients across 63 intensive care units (ICUs), in 17 countries. The primary measure of cost-effectiveness was the cost per quality-adjusted life year (QALY). Costs were estimated for each patient by multiplying resource use data by the relevant country-specific resource unit cost. QALYs were calculated using utility scores derived from the EQ-5D-5L administered at 6-month follow-up.

FINDINGS: There were no significant differences in costs or QALYs at 6 months between groups. The incremental net monetary benefit was also not significant at a willingness-to-pay threshold of $50,000 per QALY, with the 95 % CI including both negative and positive values.

INTERPRETATION: This analysis found that the cost-effectiveness of mild hypercapnia is highly uncertain when compared with normocapnia in adult patients following OHCA, with no significant differences in either costs or outcomes. Further research is required to determine the specific circumstances under which mild hypercapnia may provide value for money.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Lee YY, Eastwood G, Bailey MJ, et al. The cost-effectiveness of mild hypercapnia after out-of-hospital cardiac arrest: a health economic evaluation alongside the TAME study. Resuscitation. 2025. PMID: 41176021. doi:10.1016/j.resuscitation.2025.110878

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。